Neuroprotective effect of estradiol and phytoestrogens on MPP+‐induced cytotoxicity in neuronal PC12 cells
暂无分享,去创建一个
[1] D. Allan Butterfield,et al. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins , 2001, Mechanisms of Ageing and Development.
[2] L. Gollapudi,et al. Stable transfection of PC12 cells with estrogen receptor (ERα): Protective effects of estrogen on cell survival after serum deprivation , 1999, Journal of neuroscience research.
[3] K. Korach,et al. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. , 1996, Endocrinology.
[4] T. Di Paolo,et al. Neuroprotective properties of 17β‐estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice , 2001, Synapse.
[5] A. Collins,et al. Antioxidant efficacy of phytoestrogens in chemical and biological model systems. , 1998, Archives of biochemistry and biophysics.
[6] J. Le Bail,et al. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. , 2000, Life sciences.
[7] P. Riederer,et al. Free radicals in Alzheimer's disease. , 1998, Journal of neural transmission. Supplementum.
[8] L. Gollapudi,et al. Estrogen and NGF synergistically protect terminally differentiated, ERα‐transfected PC12 cells from apoptosis , 1999, Journal of neuroscience research.
[9] B. Sherwin. Estrogen effects on cognition in menopausal women , 1997, Neurology.
[10] J. Cooper,et al. Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement , 1992, Journal of neurochemistry.
[11] Y. Saito,et al. Expression of dopamine transporter at the tips of growing neurites of PC12 cells. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[12] J. Corton,et al. Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β. , 1998, Endocrinology.
[13] K. Jellinger. Cell death mechanisms in Parkinson's disease , 2000, Journal of Neural Transmission.
[14] E. Nestler,et al. Dopamine-receptor stimulation: biobehavioral and biochemical consequences , 2000, Trends in Neurosciences.
[15] A. Bilancio,et al. Protein Tyrosine Phosphorylation and Estradiol Action a , 1996, Annals of the New York Academy of Sciences.
[16] N. Weigel. Steroid hormone receptors and their regulation by phosphorylation. , 1996, The Biochemical journal.
[17] T. Dawson,et al. Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease , 2000, Neurobiology of Disease.
[18] T. Di Paolo,et al. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. , 2000, Current pharmaceutical design.
[19] T. Di Paolo,et al. Sex and estrous cycle variations of rat striatal dopamine uptake sites. , 1993, Neuroendocrinology.
[20] B. Goldin,et al. Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides. , 1997, Biochemical and biophysical research communications.
[21] M. Beauregard,et al. Effect of oxidative stress on stability and structure of neurofilament proteins. , 2000, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[22] Prahlad T. Ram,et al. Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors , 1998, Molecular and Cellular Endocrinology.
[23] G. Mor,et al. Raloxifene Induces Neurite Outgrowth in, Estrogen Receptor Positive PC 12 Cells , 1998, Menopause.
[24] R. Roth,et al. Estrogen Is Essential for Maintaining Nigrostriatal Dopamine Neurons in Primates: Implications for Parkinson's Disease and Memory , 2000, The Journal of Neuroscience.
[25] P. Whitten,et al. Regulation of estrogen receptor beta mRNA in the brain: opposite effects of 17beta-estradiol and the phytoestrogen, coumestrol. , 1999, Brain research. Molecular brain research.
[26] C. Behl,et al. Neuroprotective activities of estrogen: An update , 2000, Journal of neurocytology.
[27] T. Chun,et al. Phytoestrogens act as estrogen agonists in an estrogen-responsive pituitary cell line. , 1998, Toxicology and applied pharmacology.
[28] F. Holsboer,et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. , 1997, Molecular pharmacology.
[29] K. Beck,et al. Estradiol Enhances Learning and Memory in a Spatial Memory Task and Effects Levels of Monoaminergic Neurotransmitters , 1998, Hormones and Behavior.
[30] L. Doncarlos,et al. Neuroprotection by estradiol , 2001, Progress in Neurobiology.
[31] Y. Kitamura,et al. 1-Methyl-4-phenylpyridinium (MPP+)-induced cell death in PC12 cells: Inhibitory effects of several drugs , 1994, Neurochemistry International.
[32] M. Wade,et al. Interactions between endosulfan and dieldrin on estrogen-mediated processes in vitro and in vivo. , 1997, Reproductive toxicology.
[33] M. Morissette,et al. Effect of Chronic Estradiol and Progesterone Treatments of Ovariectomized Rats on Brain Dopamine Uptake Sites , 1993, Journal of neurochemistry.
[34] K. Chiba,et al. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. , 1985, Biochemical and biophysical research communications.
[35] C. Behl,et al. Estrogen Hormones Reduce Lipid Peroxidation in Cells and Tissues of the Central Nervous System , 1999, Journal of neurochemistry.
[36] P. Blanchet,et al. Effect of MPTP‐induced denervation on basal ganglia GABAB receptors: Correlation with dopamine concentrations and dopamine transporter , 2001, Synapse.
[37] D. Dluzen,et al. Inhibition of striatal dopamine transporter activity by 17beta-estradiol. , 1998, European journal of pharmacology.
[38] P. Bontempo,et al. Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells. , 1996, The EMBO journal.
[39] C. Klinge,et al. Resveratrol Acts as a Mixed Agonist / Antagonist for Estrogen Receptors a and b * , 2000 .
[40] C. Behl,et al. The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[41] Alois Jungbauer,et al. Regulation of human estrogen receptor by phytoestrogens in yeast and human cells , 1998, The Journal of Steroid Biochemistry and Molecular Biology.
[42] J. Trojanowski,et al. Induction of neurofilament triplet proteins in PC12 cells by nerve growth factor , 1982, Brain Research.
[43] N. Roehm,et al. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. , 1991, Journal of immunological methods.
[44] L. Barrier,et al. Impairment of the neuronal dopamine transporter activity in MPP+-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors , 2001, Neuroscience Letters.
[45] E. Giacobini. Aging, Alzheimer’s disease, and estrogen therapy , 1998, Experimental Gerontology.
[46] J. M. Fuentes,et al. Mechanisms of MPP+ incorporation into cerebellar granule cells , 2001, Brain Research Bulletin.
[47] C. Fall,et al. Characterization and time course of MPP+‐induced apoptosis in human SH‐SY5Y neuroblastoma cells , 1999, Journal of neuroscience research.
[48] D. Dluzen,et al. Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system , 2000, Journal of neurocytology.
[49] D. Mash,et al. Immunochemical analysis of dopamine transporter protein in Parkinson's disease , 1997, Annals of neurology.
[50] J C Rothwell,et al. Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.
[51] M. Miller,et al. Theoretical basis for the benefit of postmenopausal estrogen substitution , 1999, Experimental Gerontology.
[52] S. Fahn,et al. The effect of estrogen replacement on early Parkinson’s disease , 1999, Neurology.
[53] R J Miller,et al. The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. , 2000, Molecular pharmacology.
[54] S. Bingham,et al. Phyto-oestrogens: where are we now? , 1998, British Journal of Nutrition.
[55] M. Beal,et al. Mitochondrial dysfunction in neurodegenerative diseases. , 1998, Biochimica et biophysica acta.
[56] P. Lin,et al. The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids. , 1998, Environmental health perspectives.
[57] D. Dluzen,et al. Estrogen as a neuromodulator of MPTP-induced neurotoxicity: effects upon striatal dopamine release , 1997, Brain Research.
[58] A. Schapira,et al. Mitochondrial dysfunction in neurodegenerative disorders. , 1998, Biochimica et biophysica acta.
[59] M. Uhr,et al. Neuroprotective potential of aromatic alcohols against oxidative cell death , 1997, FEBS letters.
[60] Meharvan Singh,et al. Novel Mechanisms of Estrogen Action in the Brain: New Players in an Old Story , 1999, Frontiers in Neuroendocrinology.
[61] L. Frémont. Biological effects of resveratrol. , 2000, Life sciences.